PFE and BMY Related Headlines

Go Back

Nov 17, 2014 08:02AM Significant Results Announced for First Part of Phase 3 ANNEXA-A (PTLA) (BMY) (PFE)
Oct 1, 2014 08:17AM Portola Pharma (PTLA) Reports Andexanet Alfa Phase 3 Met Primary Endpoint
Aug 21, 2014 01:32PM Bristol-Myers Squibb (BMY), Pfizer (PFE) Receive FDA Approval of Eliquis sNDA for DVT and PE
Jul 17, 2014 08:07AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Entroll First Patient into Eliquis Phase IV
Jun 27, 2014 07:04AM Bristol-Myers Squibb's (BMY) Daklinza Receives Positive CHMP Opinion
May 14, 2014 03:13PM Drugs Stocks on Watch Ahead of ASCO Abstracts Release
Mar 14, 2014 01:04PM Bristol-Myers (BMY), Pfizer (PFE) Report FDA Approval of Eliquis sNDA
Jan 13, 2014 08:17AM Portola Pharmaceuticals (PTLA) Enters Second Collaboration Deal with Bristol-Myers (BMY)
Dec 19, 2013 05:02PM Bristol-Myers (BMY), Pfizer (PFE) sNDA for ELIQUIS Approved by FDA

PFE and BMY Related Press Releases

Go Back

Nov 17, 2014 08:00AM Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
Oct 1, 2014 08:00AM Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
Sep 22, 2014 08:00AM Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
Aug 30, 2014 05:15AM Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Pa
Jan 13, 2014 08:00AM Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With

PFE and BMY Related SEC Filings

Go Back